iShares Biotechnology ETF (NASDAQ:IBB) Shares Sold by Audent Global Asset Management LLC

Audent Global Asset Management LLC cut its position in iShares Biotechnology ETF (NASDAQ:IBB) by 6.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 8,644 shares of the financial services provider’s stock after selling 585 shares during the period. iShares Biotechnology ETF makes up 2.1% of Audent Global Asset Management LLC’s holdings, making the stock its 18th largest position. Audent Global Asset Management LLC’s holdings in iShares Biotechnology ETF were worth $1,259,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Alerus Financial NA acquired a new position in shares of iShares Biotechnology ETF in the third quarter valued at about $205,000. FSA Wealth Management LLC acquired a new position in shares of iShares Biotechnology ETF in the third quarter valued at about $65,000. Erste Asset Management GmbH acquired a new position in shares of iShares Biotechnology ETF in the third quarter valued at about $5,678,000. Tradition Wealth Management LLC boosted its stake in shares of iShares Biotechnology ETF by 3.3% in the third quarter. Tradition Wealth Management LLC now owns 55,847 shares of the financial services provider’s stock worth $8,131,000 after buying an additional 1,790 shares during the last quarter. Finally, Walleye Capital LLC boosted its stake in shares of iShares Biotechnology ETF by 82.7% in the third quarter. Walleye Capital LLC now owns 9,018 shares of the financial services provider’s stock worth $1,313,000 after buying an additional 4,082 shares during the last quarter. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Stock Performance

Shares of IBB opened at $141.55 on Monday. iShares Biotechnology ETF has a 52 week low of $119.95 and a 52 week high of $150.57. The stock’s 50-day moving average price is $142.71 and its 200-day moving average price is $142.06.

iShares Biotechnology ETF Announces Dividend

The business also recently announced a dividend, which was paid on Monday, September 30th. Stockholders of record on Wednesday, September 25th were paid a $0.2005 dividend. The ex-dividend date of this dividend was Wednesday, September 25th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.